This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Turner, S. T. Articles by Boerwinkle, E. Search for Related Content PubMed PubMed Citation Articles by Turner, S. T. Articles by Boerwinkle, E. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines High Blood Pressure Hazardous Substances DB HYDROCHLOROTHIAZIDE Related Collections Clinical genetics Clinical Studies

(Hypertension. 2001;37:739.)
© 2001 American Heart Association, Inc.

Scientific Contributions

C825T Polymorphism of the G Protein ß₃-Subunit and Antihypertensive Response to a Thiazide Diuretic

Stephen T. Turner; Gary L. Schwartz; Arlene B. Chapman; Eric Boerwinkle

From the Division of Hypertension, Department of Internal Medicine, Mayo Clinic and Foundation (S.T.T., G.L.S.), Rochester, Minn; Renal Division, Emory University (A.B.C.), Atlanta, Ga; and Human Genetics Center and Institute of Molecular Medicine, University of Texas-Houston Health Science Center (E.B.), Houston, Tex.

Correspondence and reprint requests to Stephen T. Turner, MD, Division of Hypertension, Department of Internal Medicine, Mayo Clinic and Foundation, 200 First St SW, Rochester, MN 55902. E-mail turner.stephen{at}mayo.edu

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
The T allele of the C825T polymorphism of the gene encoding the ß₃-subunit of G proteins has been associated with increased sodium-hydrogen exchange and low renin in patients with essential hypertension. To assess its association with blood pressure response to diuretic therapy, we measured the C825T polymorphism in 197 blacks (134 men, 63 women) and 190 non-Hispanic whites (76 men, 114 women) with essential hypertension (mean±SD age 48±7 years), who underwent monotherapy with hydrochlorothiazide for 4 weeks. Mean declines in systolic and diastolic blood pressures were 6±2 (P<0.001) and 5±1 (P<0.001) mm Hg greater, respectively, in TT than in CC homozygotes. Responses in heterozygotes were intermediate between the homozygous groups. Other univariate predictors of greater blood pressure responses included black race, female gender, higher pretreatment blood pressure, older age, lower waist-to-hip ratio, and measures of lower renin-angiotensin-aldosterone system activity. After the effects of the other predictors were considered, the TT genotype remained a significant predictor of greater declines in systolic and diastolic blood pressures. Thus, the C825T polymorphism of the G protein ß₃-subunit may help identify patients with essential hypertension who are more responsive to diuretic therapy.

Key Words: hypertension, essential • blood pressure • diuretics • proteins • genetics

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Despite the availability of numerous classes of antihypertensive drugs that act on a variety of blood pressure–regulating systems, fewer than 40% of treated hypertensives have their blood pressures adequately controlled.¹ Within each class of antihypertensive drugs, blood pressure responses vary considerably among patients, with a range of response that is several times greater than the mean response.² This interindividual variation in response is primarily due to pharmacodynamic, not pharmacokinetic, differences³ and likely reflects variation in pathophysiological mechanisms that contribute to hypertension in individual patients.⁴

It has long been suspected that interindividual variation in drug responses may be influenced by genetic factors.⁵ Recently, a polymorphism (C825T) was described in exon 10 of the gene encoding the ß₃-subunit of G proteins (GNB3),⁶ and subsequently it was found to be associated with a shortened splice variant of the Gß₃-protein that gives rise to enhanced signal transduction via pertussis toxin–sensitive G proteins.⁷ The C825T polymorphism was originally identified through studies of lymphoblasts, derived from whites with essential hypertension, in which sodium-proton antiport activity was increased as a consequence of enhanced G protein–dependent signal transduction in response to a variety of vasoactive and growth-promoting stimuli.⁸

The present study was prompted by recently reported associations of the 825T allele with obesity⁹ and with low plasma renin¹⁰ that suggest that the 825T allele might also be associated with a volume-expanded, sodium-sensitive, and therefore diuretic-responsive form of hypertension.^{11 12} Hence, our objective was to determine whether the C825T polymorphism predicts interindividual variation in blood pressure response to diuretic therapy among subjects with essential hypertension. We tested this hypothesis in a community and clinic-based biracial sample of hypertensive women and men undergoing monotherapy with a thiazide diuretic.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Sample
The sample consisted of 197 unrelated black adults (134 women, 63 men) from Atlanta, Ga, and 190 unrelated non-Hispanic white adults (76 women, 114 men) from Rochester Minn, aged 30 to 59.9 years with previously diagnosed hypertension who were participants in an ongoing study to identify predictors of blood pressure response to diuretic therapy. In Atlanta, study candidates were identified through lists of registered voters in Fulton and DeKalb counties (70%); outpatient medical clinics of Emory University Hospital, Grady Memorial Hospital, and the Atlanta Veterans Administration Hospital (15%); and other community sources, including churches and public media (15%). In Rochester, candidates were identified through the Rochester Epidemiology Project¹³ and a diagnostic index maintained by the Mayo Clinic for all residents of Olmsted County. A letter was sent to potential subjects providing information about the study. Interested candidates who contacted the study centers were considered for recruitment. Before enrollment, blood was drawn for screening hematology and chemistry profiles. To qualify for study participation, subjects had to be in good general health, with systolic blood pressure <180 and diastolic blood pressure <110 mm Hg, and they had to have no evidence by medical record review, history, physical examination, or screening laboratory studies of secondary hypertension, renal or liver dysfunction, serious heart disease, diabetes, gout, or sulfa allergy. Subjects who had been taking diuretics and were found to be hypokalemic at the screening visit were allowed to participate (as described below); however, subjects with unexplained hypokalemia were excluded. Subjects had to be able to discontinue drugs that could influence blood pressure level or the renin-angiotensin-aldosterone system or that could antagonize the effect of thiazide diuretics; however, postmenopausal women were allowed to continue hormone replacement therapy. Participants were required to read and sign a written consent form. The institutional review boards of Emory University and the Mayo Clinic approved all procedures involving study subjects in Atlanta and Rochester, respectively. All study procedures were performed in each institution’s General Clinical Research Center (GCRC) in accordance with the respective institution’s guidelines.

Participants had their antihypertensive medications withdrawn, and other contraindicated drugs were discontinued. If the participant had been taking a diuretic and their serum potassium level was <3.6 mEq/L at the screening visit, a potassium supplement (potassium chloride 20 mEq/d) was prescribed. A dietitian instructed each participant in a diet designed to provide a standard sodium intake of 2 mmol per kilogram of body weight per day. Compliance was monitored by 24-hour urine collections obtained every other week on the diet. Study subjects were seen every 2 weeks by the study nurse for blood pressure monitoring. At a minimum of 4 weeks after antihypertensive drug therapy was discontinued, subjects began taking 25 mg of hydrochlorothiazide orally each day for the next 4 weeks. Compliance was assessed by pill counts. Subjects’ weight, blood pressure, and serum potassium concentrations were remeasured after 2 and 4 weeks of diuretic therapy. Low-dose oral potassium supplements (20 to 40 mmol/d) were prescribed after 2 weeks of diuretic therapy if serum potassium was <3.4 mEq/L. At the end of the drug-free period and at the end of the diuretic-therapy period, subjects slept overnight in the GCRC. At 6 the next morning, blood for measurement of plasma aldosterone concentration, renin activity, and serum potassium concentration was drawn from subjects in the seated position after 30 minutes of ambulation.

Laboratory Procedures
Aldosterone and renin activity were determined by radioimmunoassays. Each sample was assayed in triplicate and the average used in the analyses. The C825T polymorphism was genotyped by polymerase chain reaction amplification of the relevant region of genomic DNA, followed by restriction enzyme digestion, gel electrophoresis, and ethidium bromide staining.⁶

Statistical Methods
For quantitative traits, data were summarized by calculating means and variances for each GNB3 genotype within each racial group. A 1-way ANOVA was used to assess differences in means among genotypes within each racial group. Relative frequencies of genotypes and alleles were calculated for each racial group. ² contingency tests were used to assess differences in relative frequencies between racial groups.

We used linear regression to assess whether variation in genotype made a statistically significant contribution to the prediction of systolic and diastolic blood pressure responses to hydrochlorothiazide. We first considered models that included only genotype and subsequently models that included genotype as well as covariate traits (including race, gender, pretreatment blood pressure levels, age, waist-to-hip ratio, and measures of the endocrine renin-angiotensin-aldosterone system). In preliminary analyses, we found no evidence of significant interaction between the effects of genotype and those of the other predictor traits.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Genotype and Allele Frequencies
Relative frequencies of the CC, TC, and TT genotypes differed significantly between racial groups (P<0.001), with the T allele significantly more frequent in blacks than in whites (76.1% versus 28.9%, P<0.001) (Table 1). In blacks, genotype and allele frequencies did not differ significantly between genders (P>0.5). In whites, differences in genotype frequencies between the genders also did not reach statistical significance (P>0.06); however, the T allele was significantly more frequent in men than in women (33.3% versus 22.4%, P<0.03). In each race, observed genotype frequencies did not differ significantly from those predicted by the Hardy-Weinberg law.

View this table: [in this window] [in a new window]   Table 1. Relative Frequencies of Genotypes and Alleles

Covariate Traits
Means for pretreatment systolic and diastolic blood pressure levels, waist-to-hip ratio, plasma renin activity, and plasma aldosterone concentration differed significantly between blacks and whites (Table 2). However, only the lower means for waist-to-hip ratio and plasma renin activity in blacks were consistent across all genotype groups. Because mean waist-to-hip ratio was significantly lower in women than in men in both races (P<0.001, analyses not shown), lower mean waist-to-hip ratio in blacks could be attributed to the higher percentage of women among blacks (68%) than among whites (40%; see Table 1). In contrast, because mean plasma renin activity did not differ significantly between black women and men (1.0±1.1 versus 1.1±1.1, P>0.5) and mean plasma renin activity was significantly lower in white men than white women (1.6±1.3 versus 2.1±1.4, P<0.04), gender differences could not account for lower mean PRA in blacks than whites.

View this table: [in this window] [in a new window]   Table 2. Covariate Traits

In each race, means for the covariate traits did not differ significantly among genotype groups (Table 2). However, because of racial differences in the genotype frequencies (see Table 1), means for pretreatment systolic and diastolic blood pressure levels, waist-to-hip ratio, plasma renin activity, and plasma aldosterone concentration appeared to differ significantly among genotype groups when blacks and whites were pooled (Table 2).

Association of Blood Pressure Response With Genotype
Variation in genotype was a statistically significant predictor of systolic and diastolic blood pressure responses to hydrochlorothiazide treatment (Table 3 and Figure 1). In the pooled sample, systolic and diastolic blood pressure responses increased progressively with the number of T alleles: mean declines in systolic and diastolic blood pressure were, respectively, 10.2 and 5.9 mm Hg in CC homozygotes, 13.6 and 7.8 mm Hg in TC heterozygotes, and 16.3 and 10.5 mm Hg in TT homozygotes. In pairwise contrasts between genotypes, the mean declines in systolic blood pressure were significantly greater in TC heterozygotes and TT homozygotes than in CC homozygotes (P<0.05 and P<0.001, respectively), and the mean decline in diastolic blood pressure was significantly greater in TT than in CC homozygotes (P<0.001). This same pattern of progressively greater systolic and diastolic blood pressure responses in association with the number of T alleles was observed in each race-gender group except black women (Figures 2 and 3). The differences in responses between TT and CC genotypes were greatest in white women (for systolic blood pressure response, 30.3 versus 10.0 mm Hg, respectively; for diastolic blood pressure response, 12.3 versus 5.8 mm Hg, respectively).

View this table: [in this window] [in a new window]   Table 3. Univariate Predictors of Blood Pressure Response to Hydrochlorothiazide

View larger version (13K): [in this window] [in a new window]   Figure 1. Genotype-specific systolic and diastolic pressure responses to hydrochlorothiazide therapy in the pooled sample of 197 blacks (134 men, 63 women) and 190 non-Hispanic whites (76 men, 114 women) with previously diagnosed essential hypertension. The C825T genotype groups are denoted CC, CT, and TT.

View larger version (21K): [in this window] [in a new window]   Figure 2. Genotype-specific systolic blood pressure responses to hydrochlorothiazide in each race-gender subgroup. The C825T genotype groups are denoted CC, CT, and TT. BF indicates black females (n=63); BM, black males (n=134); WF, white females (n=114); and WM, white males (n=76).

View larger version (24K): [in this window] [in a new window]   Figure 3. Genotype-specific diastolic blood pressure responses to hydrochlorothiazide in each race-gender subgroup. The C825T genotype groups are denoted CC, CT, and TT. BF indicates black females (n=63); BM, black males (n=134); WF, white females (n=114); and WM, white males (n=76).

By itself, variation in genotype accounted for 3.1% and 4.5%, respectively, of interindividual variation in the systolic and diastolic blood pressure responses to hydrochlorothiazide (Table 3). Other significant univariate predictors of greater systolic and diastolic blood pressure responses to hydrochlorothiazide included higher pretreatment blood pressure levels, black race, female gender, older age, and lower plasma renin activity and urinary aldosterone excretion (Table 3). Lower waist-to-hip ratio and lower plasma aldosterone concentration were additional significant predictors of systolic and diastolic blood pressure responses, respectively.

In multiple regression models that included genotype in addition to the other predictor traits (which were considered one at a time in Table 3), genotype remained a statistically significant predictor of systolic (P<0.04) and diastolic (P<0.01) blood pressure responses to hydrochlorothiazide (models not shown). In addition to C825T genotype, pretreatment blood pressure levels, plasma renin activity, and urinary aldosterone excretion also remained significant predictors of systolic and diastolic blood pressure responses, whereas gender and age remained significant predictors of the diastolic but not the systolic blood pressure response, and race and plasma aldosterone concentration made no additional contribution to the prediction of either systolic or diastolic blood pressure response. The models that included effects of all of the predictor traits (including genotype) accounted for 32% and 18%, respectively, of interindividual variation in systolic and diastolic blood pressure responses (P<0.001 for both models).

In separate multiple regression models that considered the effects of race, gender, and age, variation in genotype was not a statistically significant predictor of waist-to-hip ratio. In models that also included waist-to-hip ratio, variation in genotype was not a statistically significant predictor of pretreatment blood pressure levels, plasma renin activity, plasma aldosterone concentration, or urinary aldosterone excretion (models not shown).

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The findings in this study suggest that among subjects with previously diagnosed essential hypertension, the C825T polymorphism of the gene encoding the ß₃-subunit of G proteins is associated with interindividual differences in blood pressure response to a thiazide diuretic. One possible inference is that the 825T allele may mark hypertensive individuals in whom elevation of blood pressure has a diuretic-responsive and therefore sodium- and volume-dependent component. It is appropriate to consider whether this observed association has a plausible mechanism or whether it might simply be explained by confounding factors.

One potential confounder is race. Consistent with previous reports, we found that the 825T allele was more frequent in blacks than in whites¹⁴ and that both black race and older age were also predictive of greater blood pressure response to hydrochlorothiazide.¹⁵ However, the relationships we observed between the C825T polymorphism and interindividual differences in blood pressure responses to hydrochlorothiazide were present in all race-gender groups except black women. Moreover, in multiple linear regression models, the C825T polymorphism remained a significant predictor of interindividual differences in blood pressure responses after the contributions of race as well as the other identified predictors of response were considered.

More relevant to potential mechanistic pathways in patients with essential hypertension, the 825T allele has also been associated with obesity,⁹ low plasma renin, and elevated aldosterone-to-renin ratio,¹⁰ all of which are correlates of volume expansion and sodium sensitivity.^{11 12} However, we did not detect significant associations of the C825T polymorphism with measures of body fat or activity of the renin-angiotensin-aldosterone system. Additional potentially relevant associations of the 825T allele have been reported with enhanced in vitro sodium-hydrogen antiport and proliferation of immortalized lymphoblasts from subjects with essential hypertension.^{16 17} Unfortunately, we did not make direct measures of sodium ion transport or cellular proliferation in the present study. Because G proteins relay signals from a wide variety of hormones and neurotransmitters and transmit them to numerous effector systems,¹⁸ it is plausible that some unidentified "gain of function" related to the 825T allele may influence the balance of intravascular fluid volume and vasoconstriction that in turn influences the blood pressure response to a thiazide diuretic.

The contribution of the C825T polymorphism to the explanation of interindividual variation in blood pressure response to the thiazide diuretic was small. Nevertheless, the magnitude of its effect was similar to that of other previously identified predictors of diuretic responsivity, including race, age, and measures of the renin-angiotensin-aldosterone system.¹⁵ Only the predictive effects of pretreatment systolic blood pressure level substantially exceeded those of the C825T polymorphism. Insofar as these results are indicative of the expected magnitude of effects of variation at other single genetic loci, clinically useful prediction of complex drug-response phenotypes, such as the antihypertensive responses to a thiazide diuretic, would appear to require measurement of the variation in multiple genetic and environmental factors. Nevertheless, our present findings provide additional evidence that direct measures of genetic variation can improve the ability to predict responses to antihypertensive drug therapy.¹⁹

In summary, the present study suggests that measured variation in the gene encoding the ß₃-subunit of G proteins predicts interindividual differences in blood pressure response to a thiazide diuretic and that the predictive effects of the C825T polymorphism are additive and similar in magnitude to those of other predictors, including race, age, and measures of the renin-angiotensin-aldosterone system. Knowledge of genetic polymorphisms that are predictive of blood pressure response to antihypertensive drugs with known mechanisms of action could provide insight into the molecular mechanisms that contribute to hypertension and aid in the tailoring of effective antihypertensive drug therapy in individual patients.

	Acknowledgments

 
This work was supported by US Public Health Service grants R01-HL53330 and funds from the Mayo Foundation. We gratefully acknowledge support from the General Clinical Research Centers at Emory University (M01-RR00039) and the Mayo Clinic, Rochester (M01-RR00585).

Received October 26, 2000; first decision December 11, 2000; accepted December 29, 2000.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Meissner I, Whisnant J, Sheps S, Schwartz G, O’Fallon W, Covalt J, Sicks J, Bailey K, Wiebers D. Detection and control of high blood pressure in the community: do we need a wake-up call? Hypertension. 1999;34:466–471.[Abstract/Free Full Text]

2. Materson B, Reda D, Cushman W, Massie B, Freis E, Kochar M, Hamburger R, Fye C, Lakshman R, Gottdiener J, Ramirez E, Henderson W. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med. 1993;328:914–921.[Abstract/Free Full Text]

3. Turner S, Schwartz G, Chapman A, Hall W, Boerwinkle E. Antihypertensive pharmacogenetics: getting the right drug into the right patient. J Hypertens. 2001;19:1–11.[Medline] [Order article via Infotrieve]

4. Laragh J, Lamport B, Sealey J, Alderman M. Diagnosis ex Juvantibus: individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension. 1988;12:223–226.[Abstract/Free Full Text]

5. Motulsky A. Drug reactions, enzymes and biochemical genetics. JAMA. 1957;165:835–837.

6. Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, Sharma A, Ritz E, Wichmann H, Jakobs K, Horsthemke B. Association of a human G-protein ß₃ subunit variant with hypertension. Nat Genet. 1998;18:45–48.[Medline] [Order article via Infotrieve]

7. Rosskopf D, Busch S, Manthey I, Siffert W. G protein ß3 gene: structure, promoter, and additional polymorphism. Hypertension. 2000;36:33–41.[Abstract/Free Full Text]

8. Siffert W, Rosskopf D, Mortiz A, Wieland T, Kaldenberg-Stasch S, Kettler N, Hartung K, Beckmann S, Jakobs K. Enhanced G protein activation in immortalized lymphoblasts from patients with essential hypertension. J Clin Invest. 1995;96:759–766.

9. Siffert W, Naber C, Walla M, Ritz E. G protein ß3 subunit 825T allele and its potential association with obesity in hypertensive individuals. J Hypertens. 1999;17:1095–1098.[Medline] [Order article via Infotrieve]

10. Schunkert H, Hense H, Doring A, Riegger G, Siffert W. Association between a polymorphism in the G protein ß3-subunit gene and lower renin and elevated diastolic blood pressure levels. Hypertension. 1998;32:510–513.[Abstract/Free Full Text]

11. Vaughan ED, Laragh JH, Gavras I, Buhler FR, Gavras H, Brunner HR, Baer L. Volume factor in low and normal renin essential hypertension: treatment with either spironolactone or chlorthalidone. Am J Cardiol. 1973;32:523–532.[Medline] [Order article via Infotrieve]

12. Rocchini AP, Key J, Bondie D, Chico R, Moorehead C, Katch V, Martin M. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med. 1989;321:580–585.[Abstract]

13. Melton L. History of the Rochester Epidemiologic Project. Mayo Clin Proc. 1996;71:266–274.[Abstract]

14. Siffert W, Forster P, Jockel K, Mvere DA, Brinkmann B, Naber C, Crookes R, Heyns A, Epplen JT, Fridey J, Freedman BI, Muller N, Stolke D, Sharma AM, Al Moutaery K, Grosse-Wilde H, Buerbaum B, Ehrlich T, Ahmad HR, Horsthemke B, Du Toit ED, Tiilikainen A, Ge J, Wang Y, Rosskopf D, Yang D, Husing J. Worldwide ethnic distribution of the G protein ß3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and black African individuals. J Am Soc Nephrol. 1999;10:1921–1930.[Abstract/Free Full Text]

15. Preston R, Materson B, Reda D, Williams D, Hamburger R, Cushman W, Anderson R. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. JAMA. 1998;280:1168–1172.[Abstract/Free Full Text]

16. Rosskopf D, Fromter E, Siffert W. Hypertensive sodium-proton exchanger phenotype persists in immortalized lymphoblasts from essential hypertensive patients. J Clin Invest. 1993;92:2553–2559.

17. Rosskopf D, Schroder K, Siffert W. Role of sodium-hydrogen exchange in the proliferation of immortalised lymphoblasts from patients with essential hypertension and normotensive subjects. Cardiovasc Res. 1995;29:254–259.[Medline] [Order article via Infotrieve]

18. Farfel Z, Bourne H, Iiri T. The expanding spectrum of G protein diseases. N Engl J Med. 1999;340:1012–1020.[Free Full Text]

19. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, Glorioso N, Lanzani C, Manunta P, Righetti M, Rivera R, Stella P, Troffa C, Zagato L, Bianchi G. Polymorphisms of -adducin and salt sensitivity in patients with essential hypertension. Lancet. 1997;349:1353–1357.[Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				J. A. Johnson Ethnic Differences in Cardiovascular Drug Response: Potential Contribution of Pharmacogenetics Circulation, September 23, 2008; 118(13): 1383 - 1393. [Full Text] [PDF]

				D. K. Arnett, A. E. Baird, R. A. Barkley, C. T. Basson, E. Boerwinkle, S. K. Ganesh, D. M. Herrington, Y. Hong, C. Jaquish, D. A. McDermott, et al. Relevance of Genetics and Genomics for Prevention and Treatment of Cardiovascular Disease: A Scientific Statement From the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group Circulation, June 5, 2007; 115(22): 2878 - 2901. [Abstract] [Full Text] [PDF]

				S. C. Hunt, Y. Xin, L. L. Wu, R. M. Cawthon, H. Coon, S. J. Hasstedt, and P. N. Hopkins Sodium Bicarbonate Cotransporter Polymorphisms Are Associated With Baseline and 10-Year Follow-Up Blood Pressures Hypertension, March 1, 2006; 47(3): 532 - 536. [Abstract] [Full Text] [PDF]

				J. M. Hollier, D. F. Martin, D. M. Bell, J.-L. Li, M. G. Chirachanchai, D. V. Menon, D. Leonard, X. Wu, R. S. Cooper, C. McKenzie, et al. Epithelial Sodium Channel Allele T594M Is Not Associated With Blood Pressure or Blood Pressure Response to Amiloride Hypertension, March 1, 2006; 47(3): 428 - 433. [Abstract] [Full Text] [PDF]

				G. S. Ginsburg, R. P. Konstance, J. S. Allsbrook, and K. A. Schulman Implications of Pharmacogenomics for Drug Development and Clinical Practice Arch Intern Med, November 14, 2005; 165(20): 2331 - 2336. [Abstract] [Full Text] [PDF]

				S. T. Turner, G. L. Schwartz, A. B. Chapman, and E. Boerwinkle WNK1 Kinase Polymorphism and Blood Pressure Response to a Thiazide Diuretic Hypertension, October 1, 2005; 46(4): 758 - 765. [Abstract] [Full Text] [PDF]

				J. A. Johnson and L. H. Cavallari Cardiovascular pharmacogenomics Exp Physiol, May 1, 2005; 90(3): 283 - 289. [Abstract] [Full Text] [PDF]

				C. W. Yancy, E. J. Benjamin, R. P. Fabunmi, and R. O. Bonow Discovering the Full Spectrum of Cardiovascular Disease: Minority Health Summit 2003: Executive Summary Circulation, March 15, 2005; 111(10): 1339 - 1349. [Full Text] [PDF]

				G. L. Schwartz and S. T. Turner Screening for Primary Aldosteronism in Essential Hypertension: Diagnostic Accuracy of the Ratio of Plasma Aldosterone Concentration to Plasma Renin Activity Clin. Chem., February 1, 2005; 51(2): 386 - 394. [Abstract] [Full Text] [PDF]

				P. Manunta and G. Bianchi Low-Salt Diet and Diuretic Effect on Blood Pressure and Organ Damage J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S43 - 46. [Abstract] [Full Text]

				M. Sartori, A. Semplicini, W. Siffert, P. Mormino, A. Mazzer, F. Pegoraro, L. Mos, M. Winnicki, and P. Palatini G-Protein {beta}3-Subunit Gene 825T Allele and Hypertension: A Longitudinal Study in Young Grade I Hypertensives Hypertension, November 1, 2003; 42(5): 909 - 914. [Abstract] [Full Text] [PDF]

				R. S. Cooper Gene-Environment Interactions and the Etiology of Common Complex Disease Ann Intern Med, September 2, 2003; 139(5_Part_2): 437 - 440. [Abstract] [Full Text] [PDF]

				C. Lenfant Clinical Research to Clinical Practice -- Lost in Translation? N. Engl. J. Med., August 28, 2003; 349(9): 868 - 874. [Full Text] [PDF]

				W. Siffert Effects of the G protein {beta}3-subunit gene C825T polymorphism: should hypotheses regarding the molecular mechanisms underlying enhanced G protein activation be revised? Focus on "A splice variant of the G protein {beta}3-subunit implicated in disease states does not modulate ion channels" Physiol Genomics, April 16, 2003; 13(2): 81 - 84. [Full Text] [PDF]

				J. L. Anderson, J. F. Carlquist, B. D. Home, and J. B. Muhlestein Cardiovascular Pharmacogenomics: Current Status, Future Prospects Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2003; 8(1): 71 - 83. [Abstract] [PDF]

				S. M. Ansell, M. J. Ackerman, J. L. Black, L. R. Roberts, and A. Tefferi Primer on Medical Genomics Part VI: Genomics and Molecular Genetics in Clinical Practice Mayo Clin. Proc., March 1, 2003; 78(3): 307 - 317. [Abstract] [PDF]

				M. T. Sciarrone, P. Stella, C. Barlassina, P. Manunta, C. Lanzani, G. Bianchi, and D. Cusi ACE and {alpha}-Adducin Polymorphism as Markers of Individual Response to Diuretic Therapy Hypertension, March 1, 2003; 41(3): 398 - 403. [Abstract] [Full Text] [PDF]

				G. D Laverman, D. de Zeeuw, and G. Navis Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy? Journal of Renin-Angiotensin-Aldosterone System, December 1, 2002; 3(4): 205 - 213. [Abstract] [PDF]

				G. L. Schwartz, A. B. Chapman, E. Boerwinkle, R. M. Kisabeth, and S. T. Turner Screening for Primary Aldosteronism: Implications of an Increased Plasma Aldosterone/Renin Ratio Clin. Chem., November 1, 2002; 48(11): 1919 - 1923. [Abstract] [Full Text] [PDF]

				C. Barlassina, C. Lanzani, P. Manunta, and G. Bianchi Genetics of Essential Hypertension: From Families to Genes J. Am. Soc. Nephrol., November 1, 2002; 13(90003): S155 - 164. [Abstract] [Full Text]

				N. Glorioso, F. Filigheddu, D. Cusi, C. Troffa, M. Conti, M. Natalizio, G. Argiolas, C. Barlassina, and G. Bianchi {alpha}-Adducin 460Trp Allele Is Associated With Erythrocyte Na Transport Rate in North Sardinian Primary Hypertensives Hypertension, February 1, 2002; 39(2): 357 - 362. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Turner, S. T. Articles by Boerwinkle, E. Search for Related Content PubMed PubMed Citation Articles by Turner, S. T. Articles by Boerwinkle, E. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines High Blood Pressure Hazardous Substances DB HYDROCHLOROTHIAZIDE Related Collections Clinical genetics Clinical Studies